Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.

GSK managed to beat analysts’ revenue predictions for the first quarter of the year, despite an 8% decline in turnover pegged back by declines in COVID-19-related products. The group posted £6. ...

GlaxoSmithKline's pitch to shareholders kicked ... 2 billion plus in sales for HIV pre-exposure prophylaxis (PrEP) drug Cabenuva (cabotegravir), hepatitis B virus (HBV) antisense drug GSK3228836 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Teva Pharmaceutical Industries Ltd. ADR-2.23% $19.91B ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

As of November 08, 2024, GSK plc had a $73.1 billion market capitalization, putting it in the 96th percentile of companies in the Pharmaceuticals industry. Currently, GSK plc’s price-earnings ratio is ...

Quant Mid Cap Fund - Direct (G) 225.06 8,29,800 2.52 Quant Large and Mid Cap Fund - Direct (IDCW) 61.30 2,26,000 1.65 Quant Large and Mid Cap Fund - Direct (B) 61.30 2,26,000 1.65 Quant Large and Mid ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was ...